Martin Schüler

Also affiliated with Heidelberg University, National Center for Tumor Diseases, Essen University Hospital, German Marine Research Consortium, West German Heart and Vascular Center Essen, University of Duisburg-Essen

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Structure of the ribosome-bound cricket paralysis virus IRES RNA”.

Structure of the ribosome-bound cricket paralysis virus IRES RNA

Nature Structural & Molecular Biology(2006)10.1038/nsmb1177

N/A

7.9DataRank · unranked

198 citations

Sean R Connell, Aurelie Lescoute, Jan Giesebrecht, Marylena Dabrowski, Birgit Schroeer +5 more

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

The Lancet Diabetes & Endocrinology(2021)10.1016/s2213-8587(21)00120-0

N/A

5.1DataRank · unranked

354 citations

Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano +20 more

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Nature Medicine(2022)10.1038/s41591-022-01931-y

N/A

3.9DataRank · unranked

240 citations

Philippe A. Cassier, Salvatore Siena, Elena Garralda, Luis Paz‐Ares, Pilar Garrido +14 more

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS -mutant Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3872

N/A

1.6DataRank · unranked

44 citations

Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow +10 more

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Thyroid(2023)10.1089/thy.2023.0363

N/A

1.2DataRank · unranked

55 citations

Mimi I. Hu, Aaron S. Mansfield, Matthew H. Taylor, Martin Schüler, Viola W. Zhu +19 more

[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial

The Lancet Oncology(2025)10.1016/s1470-2045(25)00299-2

N/A

0.434DataRank · unranked

17 citations

Manuel M Weber, Christina Laschinsky, Patrick Sandach, Timo Bartel, Alina T Küper +30 more

Early Detection of Lung Cancer Using Small RNAs

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.07.005

N/A

0DataRank · unranked

24 citations

Rastislav Horos, Franziska Trudzinski, Julia Jehn, Maurice Frank, Timothy Rajakumar +36 more

Data from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

(2023)10.1158/1078-0432.c.6532311

N/A

0DataRank · unranked

0 citations

Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow +10 more